In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president of the company’s U.S. to assume the role of senior vice president, U.S. In 2004, he was appointed senior vice president, European Marketing and Brand Commercialization. He assumed added responsibility for Greece and Israel in 2001, and for South East Europe in 2003. Giovanni joined Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. This was preceded by his work as the company’s chief commercial officer. Prior to joining Bristol Myers Squibb, she was with Pfizer for 18 years in a number of leadership positons. Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. She joined Bristol Myers Squibb in 2018 as vice president, Strategic Sourcing and Procurement, Global Product Development and Supply, managing a complex supply chain need to ensure the uninterrupted supply of medicines to our patients. As a leader, he is focused on the business value of a company culture that promotes and rewards diversity and inclusion. With a background as a physician, Giovanni has helped strengthen the company’s patient-focused culture - one driven by innovation, speed, accountability and passion.
Under his leadership, BMS is evolving its operating model in order to increase speed and competitiveness. In May 2017, he assumed the role of chairman of the board.Īs CEO, Giovanni has led the company’s focus on researching and developing transformational medicines, which includes a leading portfolio of immunotherapies that are fundamentally changing the way cancer is treated. has been chief executive officer of Bristol-Myers Squibb since May 2015 and has been serving on the company’s Board of Directors since June 2014. The closing of the deal is expected to close in Q3 2022, subject to the tender of a majority of the outstanding shares of Turning Point Therapeutics and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Giovanni Caforio, M.D. Scientists and researchers with diverse backgrounds and expertise in Brisbane, Redwood City, San Diego and San Francisco collaborate across teams. Bristol Myers Squibb’s robust and growing presence in California is transforming the way cancer and other difficult-to-treat diseases are approached. “With Bristol Myers Squibb’s leadership in oncology, strong commercial capabilities and manufacturing footprint, we will be able to further accelerate the pace at which we can bring our novel medicines to benefit people diagnosed with cancer around the world.” Welcome to Bristol Myers Squibb California. Since our founding, we have leveraged our deep scientific expertise to develop a pipeline of promising precision oncology assets.
GIOVANNI CAFIO BRYSTOL MYERSSQUIBB EMAIL FULL
The board of directors of the precision oncology company have recommended unanimously that the company’s shareholders tender their shares in Bristol Myers Squibb’s tender offer.Īthena Countouriotis - Turning Point Therapeutics President and CEO said: “Through this transaction, we will be able to harness the full potential of our precision oncology platform to advance the standard of care for cancer patients. “With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile.”Īs per the terms of the deal, Bristol Myers Squibb will launch a tender offer to acquire all of the outstanding shares of Turning Point Therapeutics at a price of $76 per share in cash. Giovanni Caforio - Bristol Myers Squibb CEO said: “The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset. Photo courtesy of Bristol-Myers Squibb Company. Bristol Myers Squibb to acquire precision oncology company Turning Point Therapeutics for $4.1bn.
0 kommentar(er)
